Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Apr 9:48:49-53.
doi: 10.1016/j.jdcr.2024.03.020. eCollection 2024 Jun.

Treatment of prolonged drug reaction with eosinophilia and systemic symptoms syndrome with dupilumab using a molecularly-guided approach

Kailyn Valido  1 , Vandan Patel  2 , Michael J Murphy  1 , Muhammad H Junejo  1 , Devisha K Patel  3 , Alana Deutsch  1 , Noel Turner  1 , Theodore D Zaki  1 , Brett King  1 , William Damsky  1   4 , Caroline A Nelson  1
Affiliations
Case Reports

Treatment of prolonged drug reaction with eosinophilia and systemic symptoms syndrome with dupilumab using a molecularly-guided approach

Kailyn Valido et al. JAAD Case Rep. .
No abstract available

Keywords: DRESS; RNA in situ hybridization; drug reaction with eosinophilia and systemic symptoms; dupilumab; leflunomide.

PubMed Disclaimer

Conflict of interest statement

Dr Damsky is a consultant for Pfizer, Incyte, Eli Lilly, and TWi Biotechnology, and has research funding from Pfizer, Advanced Cell Diagnostics/Bio-techne, and AbbVie and receives licensing fees from EMD/Millipore/Sigma, all outside the submitted work. Dr Nelson has received research grants from Boehringer Ingelheim and participated in an advisory board for work related to pustular psoriasis and palmoplantar pustulosis. All other authors have no relevant conflicts to disclose.

Figures

Fig 1
Fig 1
Histology and cytokine staining. Skin biopsy specimen of the left thigh revealing spongiosis, focal vacuolar change, and a mixed inflammatory infiltrate. (Hematoxylin and eosin, 100× magnification (A), 200× magnification (B)). mRNA in situ hybridization (RISH) staining (red chromogen) for IL13 (C) and IFNG (D). H&E, Hematoxylin and eosin; IFNG, interferon gamma; IL13, interleukin 13.
Fig 2
Fig 2
Treatment timeline. Treatment timeline and clinical photos of our patient with prolonged, steroid-dependent DRESS. CS, Corticosteroids; DKA, diabetic ketoacidosis; DRESS, drug reaction with eosinophilia and systemic symptoms; MMF, mycophenolate mofetil. ∗Prednisone equivalent dosing. ∗∗Dupilumab dosing: initial loading dose of 600 mg (2 × 300 mg), followed by 300 mg every 2 weeks.
See this image and copyright information in PMC

References

    1. Kardaun S.H., Sidoroff A., Valeyrie-Allanore L., et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156(3):609–611. - PubMed
    1. Naranjo C.A., Busto U., Sellers E.M., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. - PubMed
    1. Uppal M., Rai R., Srinivas C.R. Leflunomide induced drug rash and hepatotoxicity. Indian J Dermatol. 2004;49(3):154–155.
    1. Shastri V., Betkerur J., Kushalappa P.A., Savita T.G., Parthasarathi G. Severe cutaneous adverse drug reaction to leflunomide: a report of five cases. Indian J Dermatol Venereol Leprol. 2006;72(4):286–289. - PubMed
    1. Do-Pham G., Charachon A., Duong T.A., et al. Drug reaction with eosinophilia and systemic symptoms and severe involvement of digestive tract: description of two cases. Br J Dermatol. 2011;165(1):207–209. - PubMed

Publication types

LinkOut - more resources